Results 191 to 200 of about 129,172 (353)

Meta-analysis of stage-specific <i>Calanus finmarchicus</i> vertical distribution in relation to hydrography and chlorophyll in the North Atlantic. [PDF]

open access: yesJ Plankton Res
Chamorro E   +14 more
europepmc   +1 more source

A REVISION OF THE DICTYOSTELIUM DISCOIDEUM CELL CYCLE [PDF]

open access: yes, 1984
David, Charles N.   +2 more
core  

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Aberrant activation of type 2 ryanodine receptors (RyR2) causes lethal arrhythmias, such as catecholaminergic polymorphic ventricular tachycardia (CPVT). Developing drugs that suppress RyR2 hyperactivation may be key to novel arrhythmia treatments.
Nagomi Kurebayashi   +29 more
wiley   +1 more source

Alternative Polyadenylation Drives Runaway Pro‐Inflammatory Macrophages in Periodontitis by Enabling Escape From miRNA Repression

open access: yesCell Proliferation, EarlyView.
APA‐Guided Therapeutic miRNA Selection for Periodontitis. ABSTRACT Periodontitis is a chronic inflammatory disease driven by a dysregulated host immune response, in which macrophage‐mediated inflammation shifts from protective to pathological. While monocyte‐derived macrophages (MDMs) are known to adopt a destructive, M1‐like pro‐inflammatory phenotype,
Jing Zhang   +6 more
wiley   +1 more source

Arsenite methyltransferase 3 is required for mitochondrial function and hepatic lipid metabolism

open access: yesThe FEBS Journal, EarlyView.
AS3MT is a protein that helps the body process arsenic, a naturally occurring toxin found in water and soil. We discovered it also helps cells make and use energy properly. Without AS3MT, cells' mitochondria do not work well, leading to fatty liver and reduced activity. Increasing AS3MT in liver cells restores energy and protects against arsenic damage,
Patrice Delaney   +10 more
wiley   +1 more source

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half‐life FVIII (EHL‐FVIII) and non‐FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non‐factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can ...
Jessica Garcia   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy